Actinogen secures $16.8m to fund pivotal Alzheimer’s trial beyond topline results

The latest announcement is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical shareholders approved all six resolutions at a general meeting, including the issuance of placement shares to CEO Dr Steven Gourlay and non-executive directors, who collectively subscribed for A$667,000 at 4.2 cents per share. The equity raising totals A$16.8 million, providing funding beyond the expected topline results of the pivotal XanaMIA Phase 2b/3 trial in Alzheimer’s patients due in November, strengthening the company’s clinical runway and financial position as it advances Xanamem.

The successful capital raising and board participation underscore internal confidence in Actinogen’s lead asset and support the planned XanaMIA open-label extension and broader development strategy. For investors and stakeholders, the extended funding horizon reduces near-term financing risk while positioning the company to capitalise on potentially value-defining Alzheimer’s trial data and further validate its cortisol-focused therapeutic approach.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an ASX-listed biotechnology company developing Xanamem, a novel cortisol-modulating therapy for neurological and neuropsychiatric disorders, particularly Alzheimer’s disease. The company targets diseases linked to dysregulated brain cortisol, addressing a substantial unmet medical need in cognitive impairment, depression and related conditions through late-stage clinical trials in Australia and the U.S.

Average Trading Volume: 4,898,627

Technical Sentiment Signal: Sell

Current Market Cap: A$135.9M

Learn more about ACW stock on TipRanks’ Stock Analysis page.